On Friday, August 15, the FDA approved Wegovy (semaglutide) as the first-ever GLP-1 therapy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — a pivotal moment in the fight against steatotic liver disease. It’s a breakthrough years in the making and one that could transform how we care for millions of Americans living with this silent, progressive, and deadly disease.

But approval is only the beginning. Now comes the harder part: identifying the right patients, detecting the disease earlier, and monitoring outcomes so that this promising treatment is effective at scale.

We’re standing at the edge of a new era in liver health. The question is whether our healthcare system is ready to meet the moment.

The stealth threat of MASH

MASH, a more severe form of meta

See Full Page